Radiotherapy, Small Cell Lung Cancer Limited Stage
Conditions
Keywords
small cell lung cancer limited stage, twice-daily radiotherapy, simultaneous integrated boosting technique
Brief summary
This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial. In order to establish whether the SIB technique can improve the results of twice-daily chemo-RT for patients with LS-SCLC, the investigators will primarily compare survival of patients treated with standard chemotherapy (cisplatin and etoposide) and either SIB twice-daily RT or standard dose twice-daily RT.
Detailed description
Three hundred and twenty-six patients with a histological or cytological proven diagnosis of SCLC will be recruited from 35 centers in 14 areas including provinces, municipalities and autonomous region, from May 2017 to May 2020.
Interventions
RADIATIONSIB
patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
RADIATIONStandard
patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
Sponsors
Sun Yat-sen University
Fudan University
Xijing Hospital
Henan Cancer Hospital
Jilin Provincial Tumor Hospital
First Affiliated Hospital of Xinjiang Medical University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Air Force General Hospital of the PLA
China-Japan Friendship Hospital
Peking University Third Hospital
Peking Union Medical College Hospital
Beijing Hospital
Beijing Chao Yang Hospital
Peking University People's Hospital
Peking University First Hospital
Anhui Shi, MD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Read the patient information and Sign the informed consent before enrollment * Either sex, age ≥18 and ≤70 * Histologically or cytologically confirmed SLCL * Limited stage disease(AJCC, 2009 version 7), stage I-III(T any, N any, M0) that can be safely treated with definitive radiation doses, excludes T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan, clinical nonmalignant diagnosis by investigator when the pleural is too few to obtain cytological evidence. * measurable lesion according RECIST 1.1 * PS ECOG 0-1 * having zero to two cycles of systemic chemotherapy with etoposide and cisplatin (cisplatin 60-80 mg/m2 at day1 or divided into two to three days, etoposide 100-120 mg/m2 at day 1 to 3, Q21d, and the treatment delay between two cycles shouldn't be more than 14days). * patients especially female patients must satisfy the investigator that they are not pregnant, or are not of childbearing potential, or are using adequate contraception. Man must also use adequate contraception * adequate haematological function: white blood cell ≥3.0×109/L , neutrophils ≥1.5×109/L, platelet ≥100×109/L, hemoglobin ≥90g/L. * adequate liver and renal function: total bilirubin ≤1.5 ×upper limit normal , alanine transaminase and aspartate aminotransferase ≤1.5 ×upper limit normal, normal serum creatinine and/or calculated creatinine clearance ≥60ml/min.
Exclusion criteria
* prior surgical resection of the primary tumor or prior RT for lung cancer * mixed small-cell and non-small-cell histological features * contemporaneous immunotherapy or target therapy * pregnancy or lactation * physical or mental disease that could impact treatment plan * unable to understand the trial, or could not follow the process * to refuse the sign the informed consent. * no history of previous malignancy in the past 5 years (except non-melanomatous skin or in situ servix carcinoma) * be allergic to any known protocol in this trail * be enrolled in other clinical trial in past 30days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 5 years | from the starting date of treatment until the date of death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local Progression Free Survival | 5 years | from the starting date of treatment until the date of local disease progression |
| Metastasis Free Survival | 5 years | from the staring date of treatment until the date of distant metastasis |
| health related quality of life | from baseline, immediately after radiotherapy and an average of 3 months up to 24 months. Then through study completion, an average of 6 months.From date of randomization until the date of death from any cause, assessed up to 120 months. | assessed from completed questionnaires. Assessments using Physicians Global Assessment to measure quality of life. |
| acute and late toxicity | from baseline, immediately after radiotherapy and an average of 1 week up to 12 weeks, an average of 3 months up to 24 months. Up to 120 weeks. | acute toxicity (defined as toxicity occurring between the start of treatment and up to 3 months after completion of treatment, and assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[version 5.0\]), late toxicity (more than 3 months after completion of treatment, and assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[version 5.0\]) |
Countries
China
Outcome results
None listed